To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

A combination of the immu… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases

Journal article
Authors N. S. Meagher
L. Wang
P. F. Rambau
M. P. Intermaggio
D. G. Huntsman
L. R. Wilkens
M. A. El-Bahrawy
R. B. Ness
K. Odunsi
H. Steed
E. Herpel
M. S. Anglesio
B. Zhang
N. Lambie
A. J. Swerdlow
J. Lubiński
R. A. Vierkant
E. L. Goode
U. Menon
A. Toloczko-Grabarek
O. Oszurek
S. Bilic
A. Talhouk
M. García-Closas
Q. Wang
A. Tan
R. Farrell
C. J. Kennedy
M. Jimenez-Linan
Karin Sundfeldt
J. L. Etter
J. Menkiszak
M. T. Goodman
P. Klonowski
Y. Leung
S. J. Winham
K. B. Moysich
S. Behrens
T. Kluz
R. P. Edwards
J. Gronwald
F. Modugno
B. Y. Hernandez
C. Chow
L. E. Kelemen
G. L. Keeney
M. E. Carney
Y. Natanzon
G. Robertson
R. Sharma
S. A. Gayther
J. Alsop
H. Luk
C. Karpinskyj
I. Campbell
P. Sinn
A. Gentry-Maharaj
P. Coulson
J. Chang-Claude
M. Shah
M. Widschwendter
K. Tang
M. J. Schoemaker
J. M. Koziak
L. S. Cook
J. D. Brenton
F. Daley
Björg Kristjansdottir
Constantina Mateoiu
M. C. Larson
P. R. Harnett
A. Jung
A. deFazio
K. L. Gorringe
P. D. P. Pharoah
P. Minoo
C. Stewart
O. F. Bathe
X. Gui
P. Cohen
S. J. Ramus
M. Köbel
Published in Modern Pathology
Volume 32
Pages 1834–1846
ISSN 0893-3952
Publication year 2019
Published at Sahlgrenska Cancer Center
Institute of Clinical Sciences, Department of Obstetrics and Gynecology
Pages 1834–1846
Language en
Links dx.doi.org/10.1038/s41379-019-0302-...
Subject categories Pathology

Abstract

Primary ovarian mucinous tumors can be difficult to distinguish from metastatic gastrointestinal neoplasms by histology alone. The expected immunoprofile of a suspected metastatic lower gastrointestinal tumor is CK7−/CK20+/CDX2+/PAX8−. This study assesses the addition of a novel marker SATB2, to improve the diagnostic algorithm. A test cohort included 155 ovarian mucinous tumors (105 carcinomas and 50 borderline tumors) and 230 primary lower gastrointestinal neoplasms (123 colorectal adenocarcinomas and 107 appendiceal neoplasms). All cases were assessed for SATB2, PAX8 CK7, CK20, and CDX2 expression on tissue microarrays. Expression was scored in a 3-tier system as absent, focal (1–50% of tumor cells) and diffuse (>50% of tumor cells) and then categorized into either absent/present or nondiffuse/diffuse. SATB2 and PAX8 expression was further evaluated in ovarian tumors from an international cohort of 2876 patients (expansion cohort, including 159 mucinous carcinomas and 46 borderline mucinous tumors). The highest accuracy of an individual marker in distinguishing lower gastrointestinal from ovarian mucinous tumors was CK7 (91.7%, nondiffuse/diffuse cut-off) followed by SATB2 (88.8%, present/absent cut-off). The most effective combination was CK7 and SATB2 with accuracy of 95.3% using the 3-tier interpretation, absent/focal/diffuse. This combination outperformed the standard clinical set of CK7, CK20 and CDX2 (87.5%). Re-evaluation of outlier cases confirmed ovarian origin for all but one case. The accuracy of SATB2 was confirmed in the expansion cohort (91.5%). SATB2 expression was also detected in 15% of ovarian endometrioid carcinoma but less than 5% of other ovarian histotypes. A simple two marker combination of CK7 and SATB2 can distinguish lower gastrointestinal from ovarian primary mucinous tumors with greater than 95% accuracy. PAX8 and CDX2 have value as second-line markers. The utility of CK20 in this setting is low and this warrants replacement of this marker with SATB2 in clinical practice. © 2019, The Author(s), under exclusive licensc to United States & Canadian Academy of Pathology.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?